Back
Equifax, Inc. 10K Form
Sell
30
EFX
Equifax, Inc.
Last Price:
$202.66
Seasonality Move:
6.28%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-22 | 10Q | EFX/Equifax, Inc. Quarterly |
| 2024-02-22 | 10K | EFX/Equifax, Inc. Annual |
| 2023-10-23 | 10Q | EFX/Equifax, Inc. Quarterly |
| 2023-07-25 | 10Q | EFX/Equifax, Inc. Quarterly |
| 2023-04-20 | 10Q | EFX/Equifax, Inc. Quarterly |
| 2023-02-23 | 10K | EFX/Equifax, Inc. Annual |
Receive EFX News And Ratings
See the #1 stock for the next 7 days that we like better than EFX
EFX Financial Statistics
Sales & Book Value
| Annual Sales: | $6.1B |
|---|---|
| Cash Flow: | $340.8M |
| Price / Cash Flow: | 21.84 |
| Annual Sales: | $38.24 |
| Price / Book: | 5.22 |
Profitability
| EPS (TTM): | 5.32530 |
|---|---|
| Net Income (TTM): | $664.3M |
| Gross Margin: | $2.7B |
| Return on Equity: | 13.24% |
| Return on Assets: | 5.61% |
Equifax, Inc. Earnings Forecast
Key Equifax, Inc. Financial Ratios
-
The Gross Profit Margin over the past 46 years for EFX is 44.60%.
-
The Selling, General & Administrative Expenses for EFX have been equal to 26.57% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 31.96% of Operating Income.
-
The Net Earning history of EFX is 10.94% of Total Revenues.
-
Per Share Earnings over the last 46 years have been positive in 24 years.
Equifax, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Professional Services |
| Sector: | Industrials |
| Current Symbol: | EFX |
| CUSIP: | 294429 |
| Website: | equifax.com |
Debt
| Debt-to-Equity Ratio: | 1.11 |
|---|---|
| Current Ratio: | 0.6 |
| Quick Ratio: | 0.52 |
Price-to-Earnings
| Trailing P/E Ratio: | 37.52 |
|---|---|
| Forward P/E Ratio: | 19.11 |
EFX Technical Analysis vs Fundamental Analysis
Sell
30
Equifax, Inc. (EFX)
is a Sell
Is Equifax, Inc. a Buy or a Sell?
-
Equifax, Inc. stock is rated a SellThe current Equifax, Inc. [EFX] share price is $199.59. The Score for EFX is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.